AI-generated summary
The authors report a study of a triple combination for refractory vitiligo, using a 308-nm excimer lamp, fractional CO2 laser and topical halometasone cream. In a trial of 98 patients, the combination was associated with a 50% success rate in phototherapy platform-stage lesions versus 10% in controls, but acral lesions showed no significant difference.
- Participants
- 98
- Who or what was studied
- Patients with refractory non-segmental vitiligo, including acral vitiligo and phototherapy platform-stage vitiligo (98 individuals with 158 lesions), plus 64 fresh human foreskin samples used for laser and formulation testing
- Wavelengths
- 308 nm
- Limits stated in the abstract
- The abstract does not describe a control group in the same way for all lesion types, and the acral result was not statistically significant (P = 0.425).
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
The full abstract is not shown here because it is protected by the publisher’s copyright. Read it on link.springer.com.
Record from PubMed, a service of the National Library of Medicine.
Light parameters mentioned
Found in the title and abstract by pattern. They may be incomplete, so check the paper before comparing studies.
- Wavelength
- 308 nm
How to read a trial: what to check before relying on this kind of research.
Terms in this paper: Laser, Phototherapy. Each links to its definition in the glossary.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.